Mineralys Appoints Jeffrey Munsie as CLO with 90k Options, 67.9k RSUs
Mineralys Therapeutics has appointed Jeffrey A. Munsie as Chief Legal Officer, bringing nearly 25 years of biopharma legal experience at Orbital, Concert and Merrimack Pharmaceuticals. Mineralys granted Munsie a 90,000-share option and 67,900 restricted stock units vesting over four years under its inducement award plan on March 23.
1. Appointment of Chief Legal Officer
On March 24, 2026, Mineralys Therapeutics named Jeffrey A. Munsie as Chief Legal Officer. Munsie brings nearly 25 years of legal experience in the biopharma sector, including senior roles at Orbital Therapeutics, Concert Pharmaceuticals and Merrimack Pharmaceuticals, and began his career at Wilmer Cutler Pickering Hale and Dorr.
2. Equity Awards and Vesting
On March 23, Mineralys’ Compensation Committee granted Munsie a 90,000-share stock option and 67,900 restricted stock units under its 2025 Employment Inducement Incentive Award Plan. The option vests over four years with 25% on the first anniversary and monthly vesting thereafter, while the RSUs vest 25% annually over four years.